Fig 1.
Geographic variation in cervical cancer burden (A) and recurrent or metastatic cervical cancer burden (B) across the US for the period 2017–2022, and locations of brachytherapy centers as blue circles.
Cervical cancer burden was defined as the prevalent number of cervical cancer diagnoses per 100,000 eligible female enrollees. Recurrent or metastatic cervical cancer burden was defined as the proportion of patients with cervical cancer who initiated system therapy. Contains information from OpenStreetMap and OpenStreetMap Foundation, which is licensed under the Open Data Commons Open Database License (https://www.openstreetmap.org/copyright).
Table 1.
Characteristics of eligible enrollees with cervical cancer diagnosis or initiated systemic therapy for recurrent or metastatic cervical cancer in the US (2017–2022).
Fig 2.
Association between cervical cancer screening rate and cervical cancer burden (A) and recurrent or metastatic cervical cancer burden (B) at the ZIP-3 level for the period 2017–2022.
Cervical cancer burden was defined as the prevalent number of cervical cancer diagnoses per 100,000 eligible female enrollees. Recurrent or metastatic cervical cancer burden was defined as the proportion of patients with cervical cancer who initiated system therapy. CC: cervical cancer; r/mCC: recurrent or metastatic cervical cancer.
Fig 3.
Association between percentage of families under the 200% federal poverty level in a ZIP-3 and cervical cancer burden (A) and recurrent or metastatic cervical cancer burden (B) for the period 2017–2022.
Cervical cancer burden was defined as the prevalent number of cervical cancer diagnoses per 100,000 eligible female enrollees. Recurrent or metastatic cervical cancer burden was defined as the proportion of patients with cervical cancer who initiated system therapy. CC: cervical cancer; r/mCC: recurrent or metastatic cervical cancer.
Fig 4.
Association between the percentage of population belonging to a given race/ethnicity group in a ZIP-3 and cervical cancer burden and recurrent or metastatic cervical cancer burden for the period 2017–2022.
An arrow indicates a significant association between the race/ethnicity proportion and burden, with green upwards arrows indicating positive association and red downwards arrows indicating negative association. Cervical cancer burden was defined as the prevalent number of cervical cancer diagnoses per 100,000 eligible female enrollees. Recurrent or metastatic cervical cancer burden was defined as the proportion of patients with cervical cancer who initiated system therapy. CC: cervical cancer; r/mCC: recurrent or metastatic cervical cancer.
Fig 5.
Association between recurrent or metastatic cervical cancer burden and presence of at least one brachytherapy center in a ZIP-3 for the period 2017–2022.
Recurrent or metastatic cervical cancer burden was defined as the proportion of patients with cervical cancer who initiated system therapy. r/mCC: recurrent or metastatic cervical cancer.